image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Secondary Recommendation

Concateno - Fast growing provider of drug screening services

June 2007

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • COT
  • Price:
  • 180p
Concateno (FT sector: AIM, Pharmaceuticals & Biotech), which listed as a shell company on AIM in April 2005, has established a beautiful share price graph on the back of three attractive acquisitions in the fast-growing drug screening market. This is a relatively new industry, borne out of the demand for companies who need to identify and deal with employees who abuse alcohol and / or illegal drugs, a £450m niche within the life sciences testing market, which is growing by up to 30% a year. Concateno’s first acquisition and its largest to date was the £30m purchase of London-based Medscreen, the European market leader of legally defensible drug and alcohol testing services. While saliva tests are popular bec ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Concateno - Fast growing drug screening provider eyes more deals (July 2007)
Concateno - New shell from Marwyn Capital (May 2005)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X